

§ 520.390b

with bacterial diarrhea, bacterial pulmonary infections, and bacterial infections of the urinary tract caused by susceptible organisms.

(iii) *Limitations.* Laboratory tests should be conducted, including in vitro culturing and susceptibility tests on samples collected prior to treatment. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis. Not for animals that are raised for food production. Chloramphenicol products should not be administered in conjunction with or 2 hours prior to the induction of general anesthesia with pentobarbital because of prolonged recovery. Chloramphenicol should not be administered to dogs maintained for breeding purposes. Because of potential antagonism, chloramphenicol should not be administered simultaneously with penicillin or streptomycin. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37323, Aug. 18, 1992, as amended at 62 FR 35076, June 30, 1997; 66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 2003]

§ 520.390b Chloramphenicol capsules.

(a) *Specifications.* Each capsule contains 50, 100, 250, or 500 milligrams of chloramphenicol.

(b) *Sponsor.* (1) For chloramphenicol capsules containing 50, 100, 250, or 500 milligrams of chloramphenicol see Nos. 000069, 000185, and 027454 in § 510.600(c) of this chapter.

(2) For chloramphenicol capsules containing 100 or 250 milligrams of chloramphenicol see No. 058034 in § 510.600(c) of this chapter.

(c) *Conditions of use. Dogs—*(1) *Amount.* 25 milligrams per pound of body weight every 6 hours.

(2) *Indications for use.* Oral treatment of bacterial pulmonary infections, bacterial infections of the urinary tract, bacterial enteritis, and bacterial infections associated with canine distemper caused by susceptible organisms.

(3) *Limitations.* Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment. This product must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been deter-

21 CFR Ch. I (4–1–03 Edition)

mined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37323, Aug. 18, 1992, as amended at 63 FR 5255, Feb. 2, 1998]

§ 520.390c Chloramphenicol palmitate oral suspension.

(a) *Specifications.* Each milliliter contains chloramphenicol palmitate equivalent to 30 milligrams of chloramphenicol.

(b) *Sponsor.* See No. 000856 in § 510.600(c) of this chapter.

(c) *Conditions of use. Dogs—*(1) *Amount.* 25 milligrams per pound of body weight every 6 hours. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.

(2) *Indications for use.* Treatment of bacterial pulmonary infections, infections of the urinary tract, enteritis, and infections associated with canine distemper that are caused by organisms susceptible to chloramphenicol.

(3) *Limitations.* Not for use in animals that are raised for food production. Must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37323, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]

§ 520.420 Chlorothiazide tablets and boluses.

(a)(1) *Specifications.* Each tablet contains 0.25 gram of chlorothiazide.

(2) *Sponsor.* See No. 050604 in § 510.600(c) of this chapter.

(3) *Conditions of use—*(i) *Amount.* Usual dosage is 5 to 10 milligrams per pound of body weight two or three times daily.¹

(ii) *Indications for use.* For use in dogs for treatment of congestive heart failure and renal edema.¹

(iii) *Limitations. (a)* Dosage must be adjusted to meet the changing needs of

¹These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.